{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:21:36Z","timestamp":1793172096966,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":168,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Toxicology"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.crtox.2024.100182","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:46:39Z","timestamp":1718732799000},"page":"100182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO"],"prefix":"10.1016","volume":"7","author":[{"given":"Umme","family":"Sabrina Haque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kohut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crtox.2024.100182_b0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JND-221648","article-title":"The dilemma of choice for duchenne patients eligible for Exon 51 skipping the european experience","volume":"10","author":"Aartsma-Rus","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.crtox.2024.100182_b0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/nat.2018.0756","article-title":"A sequel to the eteplirsen saga: eteplirsen is approved in the united states but was not approved in Europe","volume":"29","author":"Aartsma-Rus","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.crtox.2024.100182_b0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.crtox.2024.100182_b0020","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1261\/rna.653607","article-title":"Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications","volume":"13","author":"Aartsma-Rus","year":"2007","journal-title":"RNA"},{"key":"10.1016\/j.crtox.2024.100182_b0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng0493-283","article-title":"The structural and functional diversity of dystrophin","volume":"3","author":"Ahn","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.crtox.2024.100182_b0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse drug reactions and toxicity of the food and drug administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.crtox.2024.100182_b0466","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0169-409X(94)90016-7","article-title":"The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system","volume":"13","author":"ALLEN","year":"1994","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.crtox.2024.100182_b0471","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate","volume":"18","author":"AMANTANA","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.crtox.2024.100182_b0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.crtox.2024.100182_b0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.nmd.2017.11.018","article-title":"Cognitive profile in Duchenne muscular dystrophy boys without intellectual disability: The role of executive functions","volume":"28","author":"Battini","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.crtox.2024.100182_b0045","unstructured":"BILAL ABUASAL H.R., A., BHATTARAM C.G., SABARINATH, SREEDHARAN 2019. Golodirsen Non-Clinical Review(S), Application Number: 211970Orig1s000. U.S. Food & Drug Administration: CENTER FOR DRUG EVALUATION AND RESEARCH."},{"key":"10.1016\/j.crtox.2024.100182_b0050","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: Analysis of more than 7,000 duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.crtox.2024.100182_b0055","doi-asserted-by":"crossref","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","article-title":"Life expectancy in duchenne muscular dystrophy: Reproduced individual patient data meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.crtox.2024.100182_b0060","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: A phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.crtox.2024.100182_b0065","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JND-220811","article-title":"Long-term functional efficacy and safety of viltolarsen in patients with duchenne muscular dystrophy","volume":"9","author":"Clemens","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.crtox.2024.100182_b0070","unstructured":"DAIICHI SANKYO CO., L. 2023. Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy [Online]. NCBI. Available: https:\/\/clinicaltrials.gov\/study\/NCT04433234 [Accessed Apr 22 2024]."},{"key":"10.1016\/j.crtox.2024.100182_b0075","doi-asserted-by":"crossref","unstructured":"Deisch, J. 2017. Muscle and Nerve Development in Health and Disease.","DOI":"10.1016\/B978-0-323-37101-8.00135-1"},{"key":"10.1016\/j.crtox.2024.100182_b0477","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients","volume":"29","author":"DUAN","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.crtox.2024.100182_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.crtox.2024.100182_b0085","unstructured":"DYNE THERAPEUTICS, I. 2024. Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints."},{"key":"10.1016\/j.crtox.2024.100182_b0090","unstructured":"ENTRADA THERAPEUTICS, I. 2022. Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy."},{"key":"10.1016\/j.crtox.2024.100182_b0095","unstructured":"ENTRADA THERAPEUTICS, I. 2023. Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy. Entrada Therapeutics, Inc."},{"key":"10.1016\/j.crtox.2024.100182_b0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JND-160194","article-title":"Cardiac involvement classification and therapeutic management in patients with duchenne muscular dystrophy","volume":"4","author":"Fayssoil","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.crtox.2024.100182_b0105","unstructured":"FDA. 2016. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy [Online]. U.S. Food & Drug Administration. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy [Accessed January 01, 2024]."},{"key":"10.1016\/j.crtox.2024.100182_b0110","unstructured":"FDA. 2019. FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation [Online]. U.S. Food & Drug Administration. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation [Accessed January 01, 2024]."},{"key":"10.1016\/j.crtox.2024.100182_b0115","unstructured":"FDA. 2020a. FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation [Online]. U.S. Food & Drug Administration. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation [Accessed January 01, 2024]."},{"key":"10.1016\/j.crtox.2024.100182_b0120","unstructured":"FDA 2020b. VILTEPSO (viltolarsen) injection, for intravenous use. U.S. Food & Drug Administration."},{"key":"10.1016\/j.crtox.2024.100182_b0125","unstructured":"FDA 2021a. AMONDYS 45 (casimersen) injection, for intravenous use. U.S. Food & Drug Administration."},{"key":"10.1016\/j.crtox.2024.100182_b0130","unstructured":"FDA. 2021b. FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation [Online]. U.S. Food & Drug Administration. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0 [Accessed January 01, 2024]."},{"key":"10.1016\/j.crtox.2024.100182_b0135","unstructured":"FDA. 2024. Drugs@FDA: FDA-Approved Drugs [Online]. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm [Accessed January 01, 2024]."},{"key":"10.1016\/j.crtox.2024.100182_b0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14712598.2023.2169070","article-title":"Next steps for the optimization of exon therapy for Duchenne muscular dystrophy","volume":"23","author":"Filonova","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.crtox.2024.100182_b0145","doi-asserted-by":"crossref","unstructured":"FLANIGAN, K.M. 2014. Duchenne and Becker muscular dystrophies. Neurol Clin, 32, 671-88, viii.","DOI":"10.1016\/j.ncl.2014.05.002"},{"key":"10.1016\/j.crtox.2024.100182_b0150","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.crtox.2024.100182_b0155","unstructured":"FREED, L. M. 2020. Viltolarsen Non-Clinical Review(s), Application Number: 212154Orig1s000. U.S. Food & Drug Administration: CENTER FOR DRUG EVALUATION AND RESEARCH."},{"key":"10.1016\/j.crtox.2024.100182_b0160","unstructured":"Freed, L.M. 2021. Casimersen Non-Clinical Review(S), Application Number: 213026Orig1s000. U.S. Food & Drug Administration: CENTER FOR DRUG EVALUATION AND RESEARCH."},{"key":"10.1016\/j.crtox.2024.100182_b0165","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The dystrophin complex: Structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.crtox.2024.100182_b0469","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"GEARY","year":"2015","journal-title":"Advanced drug delivery reviews"},{"key":"10.1016\/j.crtox.2024.100182_b0170","series-title":"Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy","author":"Globenewswire","year":"2022"},{"key":"10.1016\/j.crtox.2024.100182_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/cells12192395","article-title":"Enhancing antisense oligonucleotide-based therapeutic delivery with DG9, a versatile cell-penetrating peptide","volume":"12","author":"Haque","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.crtox.2024.100182_b0180","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.crtox.2024.100182_b0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.crtox.2024.100182_b0190","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.crtox.2024.100182_b0195","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.crtox.2024.100182_b0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","article-title":"Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation","volume":"6","author":"Hudziak","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.crtox.2024.100182_b0205","doi-asserted-by":"crossref","unstructured":"Iannaccone, S.H.P., Straub, V., Muntoni, F., Wolf, D., Malhotra, J., Chu, R., Darton, E., Mercuri, E. 2022. Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: Interim results from the Phase 3 ESSENCE trial. Neuromuscular Disorders.","DOI":"10.1016\/j.nmd.2022.07.248"},{"key":"10.1016\/j.crtox.2024.100182_b0210","unstructured":"INC. P. 2022. PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy."},{"key":"10.1016\/j.crtox.2024.100182_b0474","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0086","article-title":"Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA","volume":"12","author":"IFF","year":"2023","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.crtox.2024.100182_b0215","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2016.16437","article-title":"Approving a problematic muscular dystrophy drug: Implications for FDA policy","volume":"316","author":"Kesselheim","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.crtox.2024.100182_b0220","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4155\/ppa.13.4","article-title":"Oligonucleotides for upregulating gene expression","volume":"2","author":"Khorkova","year":"2013","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.crtox.2024.100182_b0225","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1172\/JCI128205","article-title":"Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice","volume":"129","author":"Klein","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.crtox.2024.100182_b0230","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1164\/rccm.200503-322OC","article-title":"Quality of life, physical disability, and respiratory impairment in duchenne muscular dystrophy","volume":"172","author":"Kohler","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.crtox.2024.100182_b0235","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.nmd.2018.06.157","article-title":"DMD CLINICAL THERAPIES II: P.129A Japanese phase I\/II study of NS-065\/NCNP-01, exon 53 skipping drug, in patients with Duchenne muscular dystrophy - A dose-finding study","volume":"28","author":"Komaki","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.crtox.2024.100182_b0240","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese duchenne muscular dystrophy patients: A phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.crtox.2024.100182_b0245","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95918","article-title":"Functional correction of dystrophin actin binding domain mutations by genome editing","volume":"2","author":"Kyrychenko","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.crtox.2024.100182_b0250","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/jpm3030144","article-title":"Antisense therapy in neurology","volume":"3","author":"Lee","year":"2013","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.crtox.2024.100182_b0255","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1038\/s41467-020-17093-9","article-title":"Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression","volume":"11","author":"Lim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.crtox.2024.100182_b0260","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.crtox.2024.100182_b0265","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000358439","article-title":"Severe metabolic acidosis in adult patients with Duchenne muscular dystrophy","volume":"87","author":"Lo Cascio","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.crtox.2024.100182_b0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/mt.2010.219","article-title":"The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy","volume":"19","author":"Lu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.crtox.2024.100182_b0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051347","article-title":"Targeting the polyadenylation signal of pre-mRNA: A new gene silencing approach for facioscapulohumeral dystrophy","volume":"19","author":"Marsollier","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.crtox.2024.100182_b0280","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4330\/wjc.v7.i7.410","article-title":"Cardiac involvement in duchenne and Becker muscular dystrophy","volume":"7","author":"Mavrogeni","year":"2015","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.crtox.2024.100182_b0285","unstructured":"Meglio, M. 2024a. Clinical Potential of AOC 1044 in Treating Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping. Neurologylive."},{"key":"10.1016\/j.crtox.2024.100182_b0290","unstructured":"Meglio, M. 2024b. Positive Phase 2 Data Announced for MOMENTUM Study of Duchenne Agent SRP-5051. Neurologylive."},{"key":"10.1016\/j.crtox.2024.100182_b0295","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.crtox.2024.100182_b0300","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.crtox.2024.100182_b0305","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.crtox.2024.100182_b0310","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.crtox.2024.100182_b0315","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","article-title":"FDA approves first gene therapy for duchenne muscular dystrophy, despite internal objections","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.crtox.2024.100182_b0320","article-title":"FDA approves an HDAC inhibitor for duchenne muscular dystrophy","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.crtox.2024.100182_b0325","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fmicb.2018.00750","article-title":"Antisense phosphorodiamidate morpholino oligomers as novel antiviral compounds","volume":"9","author":"Nan","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.crtox.2024.100182_b0330","series-title":"Study Shows the Efficacy of Antisense Oligonucleotide-Based Exon 44 Skipping Drug, NS-089\/NCNP-02, for Patients With Duchenne Muscular Dystrophy (DMD)","author":"NCNP","year":"2022"},{"key":"10.1016\/j.crtox.2024.100182_b0472","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.addr.2007.09.012","article-title":"Proline-rich, amphipathic cell-penetrating peptides","volume":"60","author":"PUJALS","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.crtox.2024.100182_b0335","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/acs.biochem.6b00226","article-title":"Discovery and mechanism of highly efficient cyclic cell-penetrating peptides","volume":"55","author":"Qian","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.crtox.2024.100182_b0340","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1152\/jn.00248.2016","article-title":"Cognitive dysfunction in Duchenne muscular dystrophy: A possible role for neuromodulatory immune molecules","volume":"116","author":"Rae","year":"2016","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.crtox.2024.100182_b0345","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","article-title":"VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid","volume":"21","author":"Reeves","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.crtox.2024.100182_b0350","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1006\/geno.1993.1225","article-title":"Exon structure of the human dystrophin gene","volume":"16","author":"Roberts","year":"1993","journal-title":"Genomics"},{"key":"10.1016\/j.crtox.2024.100182_b0355","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.crtox.2024.100182_b0360","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","article-title":"Viltolarsen for the treatment of Duchenne muscular dystrophy","volume":"55","author":"Roshmi","year":"2019","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.crtox.2024.100182_b0365","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acschembio.0c00478","article-title":"Cell-penetrating peptides escape the endosome by inducing vesicle budding and collapse","volume":"15","author":"Sahni","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.crtox.2024.100182_b0370","unstructured":"SAREPTA THERAPEUTICS, I. 2019. Vyondys 53\u2122 (golodirsen) injection, for intravenous use. U.S. Food & Drug Administration."},{"key":"10.1016\/j.crtox.2024.100182_b0375","unstructured":"SAREPTA THERAPEUTICS, I. 2022. Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy."},{"key":"10.1016\/j.crtox.2024.100182_b0380","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: Absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.crtox.2024.100182_b0385","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1093\/nar\/gkaa126","article-title":"Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model","volume":"48","author":"Sheng","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.crtox.2024.100182_b0390","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.crtox.2024.100182_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101147","article-title":"Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy","volume":"31","author":"Shoti","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.crtox.2024.100182_b0400","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino antisense oligomers: Design, preparation, and properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"issue":"October 2017","key":"10.1016\/j.crtox.2024.100182_b0405","article-title":"Stunning pharmacological properties of DS-5141b, an antisense oligonucleotide consisting of 2'-O,4'-C-ethylene-bridged nucleic acids and 2'-O-methyl RNA, on dystrophin mRNA exon skipping","volume":"27","author":"Takaishi","year":"2017","journal-title":"Neuromuscular Disord."},{"key":"10.1016\/j.crtox.2024.100182_b0410","unstructured":"THERAPEUTICS, D. 2024. Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE\u2122 Platform in Developing Therapeutics for Rare Muscle Diseases."},{"key":"10.1016\/j.crtox.2024.100182_b0415","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.crtox.2024.100182_b0420","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/humu.20976","article-title":"Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase","volume":"30","author":"Tuffery-Giraud","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.crtox.2024.100182_b0425","doi-asserted-by":"crossref","first-page":"e0191164","DOI":"10.1371\/journal.pone.0191164","article-title":"Implicit learning deficit in children with Duchenne muscular dystrophy: Evidence for a cerebellar cognitive impairment?","volume":"13","author":"Vicari","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.crtox.2024.100182_b0430","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13395-015-0070-6","article-title":"Elusive sources of variability of dystrophin rescue by exon skipping","volume":"5","author":"Vila","year":"2015","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.crtox.2024.100182_b0435","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.crtox.2024.100182_b0440","series-title":"FDA Rebuffs Entrada\u2019s Attempt To Get Yearlong Hold on DMD Drug Lifted","author":"Waldron","year":"2023"},{"key":"10.1016\/j.crtox.2024.100182_b0445","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omtm.2022.07.005","article-title":"Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse","volume":"26","author":"Wein","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.crtox.2024.100182_b0450","doi-asserted-by":"crossref","DOI":"10.3390\/genes13020257","article-title":"Antisense and gene therapy options for duchenne muscular dystrophy arising from mutations in the N-terminal hotspot","volume":"13","author":"Wilton-Clark","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.crtox.2024.100182_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030778","article-title":"Recent trends in antisense therapies for duchenne muscular dystrophy","volume":"15","author":"Wilton-Clark","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.crtox.2024.100182_b0470","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1093\/nar\/gkm478","article-title":"Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity","volume":"35","author":"WU","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.crtox.2024.100182_b0460","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2350-14-29","article-title":"MLPA-based genotype-phenotype analysis in 1053 Chinese patients with DMD\/BMD","volume":"14","author":"Yang","year":"2013","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.crtox.2024.100182_b0465","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/jpc.12868","article-title":"Duchenne muscular dystrophy","volume":"51","author":"Yiu","year":"2015","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.crtox.2024.100182_b0467","doi-asserted-by":"crossref","unstructured":"TSUI, N. B., NG EK FAU - LO, Y. M. D. & LO, Y. M. 2002. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clinical chemistry, 48(10), 1647\u20131653.","DOI":"10.1093\/clinchem\/48.10.1647"},{"key":"10.1016\/j.crtox.2024.100182_b0468","doi-asserted-by":"crossref","unstructured":"IVERSEN, P. L., AIRD KM FAU - WU, R., WU R FAU - MORSE, M. M., MORSE MM FAU - DEVI, G. R. & DEVI, G. R. 2009. Cellular uptake of neutral phosphorodiamidate morpholino oligomers. Curr Pharm Biotechnol., 10(6):579-88.","DOI":"10.2174\/138920109789069279"},{"key":"10.1016\/j.crtox.2024.100182_b0473","doi-asserted-by":"crossref","unstructured":"VERDURMEN, W. P., BOVEE-GEURTS, P. H., WADHWANI, P., ULRICH, A. S., HALLBRINK, M., VAN KUPPEVELT, T. H. & BROCK, R. 2011. Preferential uptake of L- versus D-amino acid cell-penetrating peptides in a cell type-dependent manner. Chem Biol, 18, 1000-10.","DOI":"10.1016\/j.chembiol.2011.06.006"},{"key":"10.1016\/j.crtox.2024.100182_b0475","doi-asserted-by":"crossref","unstructured":"SERVAIS, L., MERCURI, E., STRAUB, V., GUGLIERI, M., SEFERIAN, A. M., SCOTO, M., LEONE, D., KOENIG, E., KHAN, N., DUGAR, A., WANG, X., HAN, B., WANG, D., MUNTONI, F. & GROUP, S.-N. S. 2022. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial. Nucleic Acid Ther, 32, 29-39.","DOI":"10.1089\/nat.2021.0043"},{"key":"10.1016\/j.crtox.2024.100182_b0476","doi-asserted-by":"crossref","unstructured":"WOODCOCK, I. R., TACHAS, G., DESEM, N., HOUWELING, P. J., KEAN, M., EMMANUEL, J., KENNEDY, R., CARROLL, K., DE VALLE, K., ADAMS, J., LAMANDE, S. R., COLES, C., TIONG, C., BURTON, M., VILLANO, D., BUTTON, P., HOGREL, J. Y., CATLING-SEYFFER, S., RYAN, M. M., DELATYCKI, M. B. & YIU, E. M. 2024. A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice. PLoS One, 19, e0294847.","DOI":"10.1371\/journal.pone.0294847"}],"container-title":["Current Research in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666027X24000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666027X24000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T02:44:39Z","timestamp":1734057879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666027X24000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":105,"alternative-id":["S2666027X24000355"],"URL":"https:\/\/doi.org\/10.1016\/j.crtox.2024.100182","relation":{},"ISSN":["2666-027X"],"issn-type":[{"value":"2666-027X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO","name":"articletitle","label":"Article Title"},{"value":"Current Research in Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crtox.2024.100182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100182"}}